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Abstract
Introduction: sorafenib, a tyrosine-kinase inhibitor, is widely used in the treatment of advanced
hepatocellular carcinoma. Drug-related toxicities are generally mild but sorafenib, as other similar
agents, may induce elevation of systemic arterial blood pressure levels in relation to an interaction
with cardiovascular system probably mediated by HIF pathway. This side effect may be particularly
critical for patients with underlying serious heart disease as it can induce acute heart failure, a life-
threatening condition, and usually such patients are excluded from active treatment with tyrosine-
kinase inhibitors. We report the case of a patient affected by advanced hepatocellular carcinoma
and serious impairment of cardiac function treated with sorafenib without any worsening of heart
function. To our knowledge this is the first report of this kind in the literature.
Case presentation: We report the case of a 74-year-old patient affected by advanced multifocal
HCV-cirrhosis related hepatocellular carcinoma and severe post-ischemic fall of left-ventricular
function with serious risk of cardiac functional impairment. The patient presented with an ECOG
performance status of 0. Blood chemistry tests showed a substantial elevation of α-fetoprotein
values and slight increases of bilirubin, of γ-GT and of GOT; the absence of encephalopathy and
ascites and the normality of coagulation parameters and of albumin led to classify the patient into
the functional class Child-Pugh A. The patients was successfully treated with sorafenib at the
reduced daily dose of 400 mg for long-time without any worsening of heart function.
Conclusion: The presented case can offer to oncologists a clinical support to take into
consideration when deciding to treat with sorafenib advanced hepatocellular carcinoma patients
presenting with serious impairment of cardiac function that are usually excluded from an active
treatment.
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Hepatocellular carcinoma (HCC) is ranked the fifth
tumor type worldwide, with an incidence of about
620,000 new cases per year[1]. Notwithstanding most
cases are detected in Asia and Africa, in highly developed
countries of the Western area its incidence is continuously
growing[1]. Until the very recent past, the treatment of
advanced HCC with conventional antineoplastic cyto-
toxic drugs never resulted in significant outcomes[2,3].
However, subsequent progresses achieved in the under-
standing and in the elucidation of the bio-molecular
mechanisms underlying the growth of HCC prompted the
development of new targeted agents, thus disclosing
promising opportunities for the treatment of this highly
vascularized tumor in which the inhibition of angiogen-
esis is likely to represent the main potential therapeutic
target. In this regard, sorafenib (Nexavar®, Bayer), an oral
multikinase inhibitor targeting several tyrosine-kinase
receptors involved in both blood vessel development and
tumor growth[4,5], is the first and the only drug which
has proved to be able to induce a statistically significant
prolongation of the overall survival in patients with
advanced HCC[6]. Sorafenib has shown a good safety
profile, being the most common side-effects mainly repre-
sented by mild or moderate asthenia, diarrhea, skin rash
with or without desquamation, and hand-foot skin reac-
tions[6]. However, sorafenib can also interfere with the
cardiovascular system inducing elevation of blood pres-
sure values, and, in a pivotal randomized trial, cardiac
events such as ischemia or myocardial infarction limited
in severity to grades 2 or 3 have been observed in about
3% of patients[6]. Consequently, this evidence must be
taken into serious consideration when facing a treatment
with sorafenib in patients displaying cardiovascular
comorbidities[7,8].
Here below we report a case of a patient with multifocal
HCC HCV-cirrhosis related who, notwithstanding the
presence of a series of cardiovascular alterations, has been
successfully treated with sorafenib without any further sig-
nificant worsening of the cardiovascular function.
Case presentation
In May 2008, a 74-year-old heavily smoker Caucasian
man was referred to our institution following ultrasonog-
raphy showing multiple lesions ranging in diameter from
0.3 to 2.0 cm in both liver lobes, without any evidence of
ascites. The patient was work retired in good state of
health (ECOG PS 0), with an history of HCV-related liver
cirrhosis well balanced while familiar history was not
medically relevant. He reported a previous history of car-
diovascular illness consisting in chronic ischemic post-
infarction cardiomyopathy leading to a substantial
decrease in left-ventricular ejection fraction (LVEF), arte-
rial hypertension, obesity (98 kg weight and 174 cm
height), stroke with cerebral vascular disease and altera-
tions of respiratory system (chronic obstructive pulmo-
nary disease).
Total-body CT scan confirmed the presence of the hepatic
lesions previously observed at ultrasonography without
any other evidence deserving consideration (Figure 1).
Blood chemistry tests showed a substantial elevation of α-
fetoprotein values (1500 mg/ml), and slight increases of
bilirubin (1.21 mg/ml), of γ-GT (116 U/L) and of GOT
(76 U/L); the absence of encephalopathy and ascites, and
the normality of coagulation parameters and of albumin
led to classify the patient into the functional class Child-
Pugh A. The echo-guided liver biopsy and the subsequent
histo-pathological assessment definitely confirmed the
diagnosis of HCC.
At the objective clinical examination the patient only dis-
played slight indolent hepatomegaly. He also showed a
good hemodynamic steadiness: no signs of heart failure
such as declivous edema, jugular turgor and pulmonary
noises have been observed. In addition, no important
symptoms, particularly those related to dyspnea or work-
load angina were complained of. The instrumental cardiac
function assessment confirmed the serious systolic dys-
function with a LVEF of 35%. The patient was on treat-
ment with bisoprolol, furosemide, ramipril and anti-
aldosterone drugs.
CT-scan of upper abdomen showing multiple hepatic lesionsFigure 1
CT-scan of upper abdomen showing multiple hepatic 
lesions. Pre-treatment hepatic evaluation performed at the 
time of initial diagnosis by CT-scan showed multiple hepatic 
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stage C according to the Barcelona-Clinic Liver Cancer
(BCLC) classification and, consequently, only amenable
to the best available systemic treatment; therefore, starting
June 2008, a treatment with sorafenib continuous dosing
at the reduced dose of 400 mg/day was started.
Instrumental assessments with ultrasound carried out
every two months showed a substantial unchanging of the
size of the hepatic lesions. Conversely, α-fetoprotein val-
ues constantly and progressively decreased up to 260 ng/
ml in June 2009, while the other hematochemical param-
eters showed an improvement of liver function indexes.
Presently the patient is continuing the treatment with sor-
afenib at the same dose. Treatment was extremely well tol-
erated without, with the exception of asthenia, the onset
of any peculiar drug-related side-effect requiring medical
interventions, drug-dose reductions or treatment discon-
tinuation. Due to the particular patient's cardiac condi-
tions, the echographic evaluation of LVEF was carried out
every two months: as it appears in Figure 2, no further
drops or significant fluctuations have been observed, and
the values of LVEF substantially remained stable over the
time.
Discussion
The results of the pivotal phase III study comparing soraf-
enib versus placebo in patients with advanced HCC
(SHARP study)[6] have unquestionably modified the nat-
ural history of this disease which, on account of its high
chemo-resistance, until recently was considered incurable.
This new tyrosine kinase inhibitor, in fact, has been able
to induce a statistically significant improvement of
patients' overall survival with a 31% reduction of risk of
death. Besides the undeniable efficacy data, the SHARP
study also highlighted the very good safety profile of sor-
afenib which induced an acceptable rate of drug-related
adverse events mainly consisting of constitutional symp-
toms, dermatologic and gastrointestinal events mostly
mild to moderate in severity: and these findings are in line
with the incidence of sorafenib-associated adverse events
observed in studies carried out in other tumor types such
as renal cell carcinoma[7,8]. However, it must be borne in
mind that the use of tyrosine kinase inhibitors could be
also associated with a risk of a series of cardiac events,
whose patho-physiological underlying mechanism still
needs to be clarified and understood. An hypothesis to
explain this peculiarity is based on the role played by
hypoxia-inducible factor α (HIFα) as response mediator
of myocardium to acute or chronic ischemia, of myocar-
dial re-modelling, of post-infarction re-vascularization
and of vascular permeability: an HIFα reduction induced
by tyrosine kinase inhibitors could interfere with these
pathways thus inducing an impairment of the normal
physiology of cardiovascular system [9-11].
As far as sorafenib is concerned, a survey of data on 2276
patients treated in phase I, II and III studies indicates that
the incidence of congestive heart failures, the worse car-
diac situation, globally accounts for 1.89%, and this figure
Behaviour of left ventricular ejection fraction values during treatmentFigure 2
Behaviour of left ventricular ejection fraction values during treatment. left ventricular ejection fraction, echocardio-
graphically evaluated every two months for one year during treatment with sorafenib, showed no further drops or significant 
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tions are considered[12]. In another investigation carried
out in an unselected population with advanced renal cell
carcinoma treated with two different tyrosine kinase
inhibitors, sorafenib and sunitinib[12], the reported inci-
dence of treatment-related LVEF reductions has been
21,4% for sorafenib and 54.5% for sunitinib. Compared
to the data coming from clinical trials, these rather high
incidences could be explained by the particular baseline
characteristics of patients showing cardiovascular clinical
signs in 33.8% of cases, and by a pre-existing ventricular
dysfunction in 12%. LVEF reductions, however, were tem-
porary and regressed following treatment discontinua-
tion[13]. Recently, a prospective phase I study to evaluate
the cardiovascular safety profile of sorafenib was carried
out in 53 patients with different solid tumors or lympho-
mas treated at the standard dose of 400 mg bid: neither
significant decreases of LVEF evaluated by MUGA scan nor
significant alterations of heart rate or of QTc interval have
been observed[14].
Referring to our case report, at baseline the patient dis-
played substantial cardiovascular disorders along with a
significant LVEF reduction classified NYHA II. Owing to
the reduced cardiac function and to the lack of more reli-
able safety data concerning patients with HCC treated
with sorafenib, a softer treatment consisting in a daily
total dose of 400 mg was planned. After 12 months of
administration, this regimen did not induce any notewor-
thy alteration of cardiac function and the LVEF is still clas-
sified NYAH II. In this regard it must be outlined that the
median duration of treatment in both randomized studies
carried out in HCC[6] and in renal cancer[7] was 5.5
months. Therefore, our possibility to administer sorafenib
for 8 months without any discontinuation further
strengthen the safety profile of the drug. All these evi-
dences strongly indicate that even in high risk patients due
to cardiovascular complications, such as the impairment
of LVEF, a treatment with sorafenib is feasible and safe
provided that a close and careful monitoring of parame-
ters of cardiac function is done.
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